Home > Formulary : Paediatric > Recent Decisions > 2022 >
Decisions 13th September 2022
Decisions 13th September 2022
At the meeting on the 13th September, the following decisions were agreed
New Drug Requests
Approved
Tretinoin 0.025% / Clindamycin 1% Gel (TLS Green)
-
For acne
-
Tretinoin/Erythromycin removed from the Formulary
Synalar® (fluocinolone ointment 0.025%) ointment/cream (TLS Blue)
-
For severe inflammatory skin disorders such as eczema and psoriasis
-
Synalar gel (already on formulary) TLS changed from green to blue inline with other formulations of Synalar.
Melatonin (TLS Red)
-
Off-label for use on PICU and HDU (during hospital stay only) to aid onset of sleep in patients with neurodevelopmental disorders/ASD and other conditions e.g. bone marrow transplant and renal patients who are suffering from sleep cycle disorder following prolonged stays and who have not responded to standard sleep hygiene measures.
Decision Pending
Melatonin (Adults and Paediatrics)
-
Off-label use for sleep disorder in adult and paediatric patients with any of:
-
Attention Deficit Hyperactivity Disorder (ADHD)
-
Autism Spectrum Disorder (ASD)
-
Learning Disabilities (LD)
-